Gene patenting and medical research: A view from a pharmaceutical company

Nature Reviews Drug Discovery

Volumn 3, Issue 4, 2004, Pages 364-368

  Stott, Mike ^a   Valentine, Jill ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GENE PRODUCT; NEW DRUG;

ARTICLE; AUTOMATION; COST BENEFIT ANALYSIS; DRUG INDUSTRY; DRUG MARKETING; DRUG TARGETING; ECONOMIC ASPECT; EVIDENCE BASED MEDICINE; FINANCIAL MANAGEMENT; GENE SEQUENCE; GENE THERAPY; GENETIC ANALYSIS; GENETIC CODE; GOVERNMENT; HUMAN; HUMAN GENETICS; INVESTMENT; LAW; MEDICAL RESEARCH; MEDICAL TECHNOLOGY; PATENT; PERCEPTION; PRIORITY JOURNAL; UNITED STATES;

EID: 16544374065     PISSN: 14741776     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrd1348     Document Type: Article

References (24)

1. Heller, M. A. & Eisenberg, R. S. Can patents deter innovation? The anticommons in biomedical research. Science 280, 698-701(1998).
2. Caulfield, T. Gold, E. R. & Cho, M. K. Patenting human genetic material: refocusing the debate. Nature Rev. Genet. 1, 227-231 (2000).
3. Andrews, L. B. Genes and patent policy: rethinking intellectual property rights. Nature Rev. Genet. 3, 803-808 (2002).
4. Nuffield Council of Bioethics. The Ethics of Patenting DNA [online] (cited 23.07.02) (2002).
5. Royal Society. Keeping Science Open: the Effects of Intellectual Property Policy on the Conduct of Science [online] (cited April 2003) (2003).
6. Doll, J. The patenting of DNA. Science 290, 689-690 (1998).
7. Arnold, B. E. & Ogielska-Zei, E. Patenting genes and genetic research: good or bad for innovation? Annu. Rev. Genomics Hum. Genet. 3, 415-432 (2002).
8. Warburg, R. J., Wellman, A., Buck, T. B. & Ligler Schoenhard, A. Patentability and maximum protection of intellectual property in proteomics and genomics. Pharmacogenomics 4, 81-90 (2003).
9. DiMasi, J. A., Hansen, R. W. & Grabowski, H. G. The price of innovation: new estimates of drug development costs. J. Health Econ. 22, 151-185 (2003).
10. McNamee, D. Seeking potential drugs in chemical libraries. Lancet 345, 1167-1168 (1995).
11. Grabowski, H., Vernon, J. & DiMasi, J. A. Returns on research and development for 1990s new drug introductions. Pharmacoeconomics 20 (Suppl. 3), 11-29 (2002).
12. EU Commission Report. Report from the Commission to the European Parliament and the Council: Development and Implications of Patent Law in the Field of Biotechnology and Genetic Engineering [online] (2002).
13. Evans Medical Ltd's Patent Reports of Patent Cases. Patent Case 517 (1998).
14. Walsh, J. P., Cohen, W. M. & Arora, A. Science and the law. Working through the patent problem. Science 299, 1021 (2003).
15. Walsh, J. P. in Patents in the Knowledge-Based Economy (eds Cohen, W. M & Merrill, S. A.) 285-340 (National Academies, Washington DC, 2003).
16. Thomas, S. M., Hopkins, M. M. & Brady, M. Shares in the human genome - the future of patenting DNA. Nature Biotechnol. 20, 1185-1188 (2002).
17. Stott, M. & Valentine, J. Impact of gene patenting on R&D and commerce. Nature Biotechnol. 21, 729-731 (2003).
18. Decision of the Opposition Division in European patent 0630405 (ICOS Corporation), dated 20th June 2001. Official J. Eur. Patent Office 293 (2002).
19. Crease, D. J. & Schlich, G. W. Is there a future for 'speculative' gene patents in Europe? Nature Rev. Drug Discov. 2, 407-410 (2003).
20. Genetic Inventions, Intellectual Property Rights and Licensing Practices, Evidence and Policies, Organisation for Econnomic Co-operation and Development [online] (cited 23.12.02) (2002).
21. US Patent and Trademark Office utility guidelines [online] (cited 05.01.01) (2001).
22. Resnik, D. B. DNA patents and scientific discovery and innovation: assessing benefits and risks. Sci. Eng. Ethics 7, 29-62 (2001).
23. Cho, M. K., Illangasekare, S., Weaver, M. A., Leonard, D. G. & Merz, J. F. Effects of patents and licenses on the provision of clinical genetic testing services. J. Molec. Diagn. 5, 3-8 (2003).
24. Stuart, J. H. Graham. in Patents in the Knowledge-Based Economy (eds Cohen, W. M & Merrill, S. A.) 74-119 (National Academies, Washington DC, 2003).